Sai Parenterals Limited
NSE: SAIPARENT · Pharmaceuticals
Snapshot
Unlock Sai Parenterals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sai Parenterals Limited is an integrated pharmaceutical company operating in branded generics, contract development and manufacturing operations (CDMO), and specialized injectables. The company runs a manufacturing network of five facilities with an installed annual capacity of approximately 1,160 million units.
Business Model
The company generates revenue by supplying branded generics, executing contract manufacturing operations, and commercializing specialized injectables across domestic and international markets.
- Annual Installed Capacity:1,160 million units
- Manufacturing Facilities:5 units
Management Commentary
Management focuses on expanding formulation pipelines through dedicated research and development while strengthening direct international distribution and regulatory presence.
Growth Outlook
Growth is anchored by a renewed 1,300 Crore INR OTC medicines supply agreement in Australia and expanded operations through Noumed, providing access to new dossiers and customer relationships in international markets.
- Australia OTC Supply Agreement:1,300 Crore INR
Key Risks
- Regulatory Compliance. Strict international and domestic regulatory standards for manufacturing facilities could impact export approvals and operational continuity.
- Concentration Risk. Heavy reliance on key international contracts, such as the major Australian supply agreement, exposes the company to client and geographic concentration risks.
- Foreign Exchange Volatility. Extensive international operations across Australia and New Zealand expose revenues and margins to currency fluctuations.
Start your research today
Unlock AI insights, financials, peers and live data on Sai Parenterals Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sai Parenterals LimitedSAIPARENT | ₹2,250 Cr | — | — | — | 10.0% | — | — | — |
Panacea BiotecPANACEABIO | ₹2,338 Cr | -309.53 | 130.50 | 10.3% | 2.6% | -1.1% | -0.4% | -10.5% |
Indoco RemediesINDOCO | ₹2,318 Cr | 786.72 | 19.67 | 12.1% | 9.0% | 0.3% | 8.4% | -13.2% |
Fredun Pharmaceuticals LimitedFREDUN | ₹2,305 Cr | 16.32 | 22.33 | — | 14.9% | 20.9% | 39.1% | +2.0% |
Windlas BiotechWINDLAS | ₹2,274 Cr | 34.22 | 18.80 | 18.5% | 13.0% | 12.2% | 16.8% | +15.1% |
Venus RemediesVENUSREM | ₹2,197 Cr | 20.67 | 12.21 | 20.9% | 21.9% | 19.0% | 23.9% | +295.8% |
As of Mar 2026
Financials
Sai Parenterals Limited
NSE: SAIPARENT · Pharmaceuticals
Snapshot
Unlock Sai Parenterals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sai Parenterals Limited is an integrated pharmaceutical company operating in branded generics, contract development and manufacturing operations (CDMO), and specialized injectables. The company runs a manufacturing network of five facilities with an installed annual capacity of approximately 1,160 million units.
Business Model
The company generates revenue by supplying branded generics, executing contract manufacturing operations, and commercializing specialized injectables across domestic and international markets.
- Annual Installed Capacity:1,160 million units
- Manufacturing Facilities:5 units
Management Commentary
Management focuses on expanding formulation pipelines through dedicated research and development while strengthening direct international distribution and regulatory presence.
Growth Outlook
Growth is anchored by a renewed 1,300 Crore INR OTC medicines supply agreement in Australia and expanded operations through Noumed, providing access to new dossiers and customer relationships in international markets.
- Australia OTC Supply Agreement:1,300 Crore INR
Key Risks
- Regulatory Compliance. Strict international and domestic regulatory standards for manufacturing facilities could impact export approvals and operational continuity.
- Concentration Risk. Heavy reliance on key international contracts, such as the major Australian supply agreement, exposes the company to client and geographic concentration risks.
- Foreign Exchange Volatility. Extensive international operations across Australia and New Zealand expose revenues and margins to currency fluctuations.
Start your research today
Unlock AI insights, financials, peers and live data on Sai Parenterals Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026